ADMAAnother day, another lawsuit notice
ADMA Biologics just picked up another reminder that the legal playlist isn’t done spinning. The Schall Law Firm is telling investors about a class action tied to alleged violations of federal securities laws, with a class period running from August 9, 2024 through March 25, 2026.
Why you should care
This isn’t a fresh operational update or a shiny new product launch. It’s the kind of headline that keeps a cloud hanging over the stock, because shareholder litigation can drag on, create headline risk, and make investors wonder what comes next.
The fine print headache
The firm says investors who bought ADMA shares during the class period should contact it before August 10th, 2026 if they want to be considered for lead plaintiff status. In other words: the legal countdown timer is still ticking, and ADMA is still wearing the blinking red badge of lawsuit season.
Big picture: when a company keeps showing up in class-action notices, it can become less about one lawsuit and more about a persistent reputational drag. That’s not exactly the kind of momentum bulls like to see.